Literature DB >> 27658169

First Successful Haploidentical Stem Cell Transplantation in Romania.

Alina Tănase, C Tomuleasa, Alexandra Mărculescu, A Bardaş, Anca Coliţă, Ş O Ciurea.   

Abstract

Hematopoietic stem cell transplantation is an established treatment for many malignant and non-malignant haematological disorders. In the current case report, we describe the first haploidentical stem cell transplantation, used for the first time in Romania, the case of a 33 year-old young woman diagnosed with Hodgkin's lymphoma that has underwent a haploSCT after she relapsed from several chemotherapy regimens, as well as after an autologous stem cell transplantation. This success represents a prèmiere in Romanian clinical hematology, being the first case of a haploSCT in Romania, as well as in South-Eastern Europe.

Entities:  

Mesh：

Year:  2016        PMID： 27658169      PMCID： PMC7252216          DOI： 10.1515/rjim-2016-0021

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN： 1220-4749


  21 in total

1.  Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Authors:  Armando Santoro; Massimo Magagnoli; Michele Spina; Graziella Pinotti; Licia Siracusano; Mariagrazia Michieli; Andrea Nozza; Barbara Sarina; Emanuela Morenghi; Luca Castagna; Umberto Tirelli; Monica Balzarotti
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

Review 2.  Allogeneic hematopoietic cell transplantation: the state of the art.

Authors:  Boglarka Gyurkocza; Andrew Rezvani; Rainer F Storb
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

3.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Authors:  Claudio G Brunstein; Ephraim J Fuchs; Shelly L Carter; Chatchada Karanes; Luciano J Costa; Juan Wu; Steven M Devine; John R Wingard; Omar S Aljitawi; Corey S Cutler; Madan H Jagasia; Karen K Ballen; Mary Eapen; Paul V O'Donnell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

4.  Marrow transplantation from related donors other than HLA-identical siblings.

Authors:  P G Beatty; R A Clift; E M Mickelson; B B Nisperos; N Flournoy; P J Martin; J E Sanders; P Stewart; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1985-09-26       Impact factor: 91.245

Review 5.  Stem cell self-renewal: lessons from bone marrow, gut and iPS toward clinical applications.

Authors:  F J T Staal; C Baum; C Cowan; E Dzierzak; S Hacein-Bey-Abina; S Karlsson; T Lapidot; I Lemischka; S Mendez-Ferrer; H Mikkers; K Moore; E Moreno; C L Mummery; C Robin; T Suda; M Van Pel; G Vanden Brink; J J Zwaginga; W E Fibbe
Journal:  Leukemia       Date:  2011-04-29       Impact factor: 11.528

6.  Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.

Authors:  P V O'Donnell; L Luznik; R J Jones; G B Vogelsang; M S Leffell; M Phelps; P Rhubart; K Cowan; S Piantados; E J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

7.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

Authors:  G P Canellos; J R Anderson; K J Propert; N Nissen; M R Cooper; E S Henderson; M R Green; A Gottlieb; B A Peterson
Journal:  N Engl J Med       Date:  1992-11-19       Impact factor: 91.245

8.  Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation.

Authors:  Ulas D Bayraktar; Denái R Milton; Michele Guindani; Gabriela Rondon; Julianne Chen; Gheath Al-Atrash; Katayoun Rezvani; Richard Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-31       Impact factor: 5.742

9.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Authors:  Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

10.  ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.

Authors:  P Selby; P Patel; S Milan; M Meldrum; J Mansi; E Mbidde; M Brada; T Perren; G Forgeson; M Gore
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640
View more
  2 in total

Review 1.  Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.

Authors:  Alexandra Traila; Patriciu Achimas-Cadariu; Delia Dima; Romeo Micu
Journal:  Cancer Manag Res       Date:  2018-06-13       Impact factor: 3.989

Review 2.  Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?

Authors:  Catalin Constantinescu; Sergiu Pasca; Tiberiu Tat; Patric Teodorescu; Catalin Vlad; Sabina Iluta; Delia Dima; Dana Tomescu; Ecaterina Scarlatescu; Alina Tanase; Olafur Eysteinn Sigurjonsson; Anca Colita; Hermann Einsele; Ciprian Tomuleasa
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.